CoChat

Right- and left-sided colorectal cancers respond differently to cetuximab

Open access
Wang, Feng, Bai, Long, Liu, Tian-Shu, Yu, Yi-Yi, He, Ming-Ming, Liu, Kai-Yan, Luo, Hui-Yan, Zhang, Dong-Sheng, Jin, Yin, Wang, Feng-Hua, Wang, Zhi-Qiang, Wang, De-Shen, Qiu, Miao-Zhen, Ren, Chao, Li, Yu-Hong, Xu, Rui-Hua · 2015 · Chinese Journal of Cancer
Cited by 75

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Right-sided colon cancer (RSCC) and left-sided colorectal cancer (LSCRC) differ with respect to their biology and genomic patterns. This study aimed to examine whether the primary tumor location is associated with the response to cetuximab in patients with metastatic colorectal cancer (mCRC). METHODS: Patients with mCRC treated with cetuximab and standard chemotherapy as first- or second-line treatments were compared with randomly chosen patients who were treated with chemotherapy alone between 2005 and 2013. The main outcome measures were the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The differences in the outcome were analyzed by using the chi-squared test, Student's t test, and Kaplan-Meier method. RESULTS: The treatment results of 206 patients with mCRC treated with cetuximab and standard chemotherapy as first- or second-line treatments were compared with those of 210 patients who were treated with chemotherapy alone. As a first-line treatment, cetuximab with chemotherapy was associated with a significantly higher ORR (49.4 % vs. 28.6 %, P = 0.005) as well as longer PFS (9.1 vs. 6.2 months, P = 0.002) and OS (28.9 vs. 20.1 months, P = 0.036) than chemotherapy alone in patients with LSCRC. However, cetuximab neither improved the ORR (36.4 % vs. 26.2 %, P = 0.349) nor prolonged PFS (5.6 vs. 5.7 months, P = 0.904) or OS (25.1 vs. 19.8 months, P = 0.553) in patients with RSCC. As a second-line treatment, cetuximab exhibited a tendency to improve the ORR (23.5 % vs. 10.2 %, P = 0.087) and prolong PFS (4.9 vs. 3.5 months, P = 0.064), and it significantly prolonged OS (17.1 vs. 12.4 months, P = 0.047) compared with chemotherapy alone in the patients with LSCRC. In contrast, as a second-line treatment, cetuximab neither improved the ORR (7.1 % vs. 11.4 %, P = 0.698) nor prolonged PFS (3.3 vs. 4.2 months, P = 0.761) or OS (13.4 vs. 13.0 months, P = 0.652) in patients with RSCC. CONCLUSIONS: The addition of cetuximab to chemotherapy in both first- and second-line treatments of mCRC may only benefit patients with primary LSCRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40880-015-0022-x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 75

Metadata

Authors
Wang, F., Bai, L., Liu, T.-S., Yu, Y.-Y., He, M.-M., Liu, K.-Y., Luo, H.-Y., Zhang, D.-S., Jin, Y., Wang, F.-H., Wang, Z.-Q., Wang, D.-S., Qiu, M.-Z., Ren, C., Li, Y.-H., & Xu, R.-H.
Venue
Chinese Journal of Cancer
Published
2015-06-10
Volume
34
Issue
3
Pages
384-93
ISSN
  • 1000-467X (ISSN-L)
  • 1944-446X
OpenAlex
W1908989187
Cited by
75
References
6
FWCI
4.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Right- and left-sided colorectal cancers respond differently to cetuximab. https://app.cochat.ai/papers/10.1186/s40880-015-0022-x
The paper
Wang, F., Bai, L., Liu, T.-S., Yu, Y.-Y., He, M.-M., Liu, K.-Y., Luo, H.-Y., Zhang, D.-S., Jin, Y., Wang, F.-H., Wang, Z.-Q., Wang, D.-S., Qiu, M.-Z., Ren, C., Li, Y.-H., & Xu, R.-H. (2015). Right- and left-sided colorectal cancers respond differently to cetuximab. Chinese Journal of Cancer. https://doi.org/10.1186/s40880-015-0022-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.